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Abstract
Classically, molecular chaperones play a pivotal role in the maintenance of cellular proteostasis and thus, in the safeguarding of the cell homeostasis while reducing 
the deleterious effects of extracellular and intracellular stresses. They are also active players in immunologically relevant scenarios such as the activation of innate 
immunity, antitumour immunity, and autoimmune diseases. It is currently accepted that misdirected immune responses may target self-antigens and generate severe 
inflammatory responses, a typical signature of autoimmune diseases. In addition to numerous components in immune responses, chaperone proteins are also detected 
in the extracellular fluids and have been implicated in autoimmune and inflammatory diseases acting as pro- and anti-inflammatory factors. In several inflammatory 
pathologies, chaperones are greatly induced as a direct consequence of the inflammatory stress and are released from the cell thanks to a poorly understood mechanism. 
These extracellular chaperones are capable to stimulate anti-inflammatory regulatory T cell responses, thereby inducing the negative feedback control of inflammation. 
Therefore, it has been proposed that immunization with heat-shock protein peptides could prevent the development of certain diseases. In this article we review the 
basics of the stress response, summarize current controversies over the role of extracellular chaperones in inflammatory reactions and autoimmunity, and discuss the 
cytoprotective and immunoregulatory roles of heat-shock proteins, a challenging subject that may open a new avenue for the drug discovery and treatment of diseases 
related to autoimmune disturbs.
Introduction to the stress response
Cells are always exposed to a number of sudden and potentially 
harmful variations of their biological milieu. With the purpose to 
protect proteins from misfolding, denaturation and/or aggregation, 
cells trigger a fast response characterized by a number of events able to 
protect them  from the hostile environment, and restore a balanced and 
safe new steady-state of protein homeostasis commonly referred to as 
‘proteostasis’ [1,2]. Importantly, such response builds a physiological 
network that shields cells and tissues from the risky challenges they may 
encounter, such as heat, cold, toxics, chemicals, UV light, radiation, 
drugs, infections, infestations, inflammation, pH variations, osmotic 
changes, nutrient deprivation, oxidative stress, hypoxia-ischemia, 
apoptotic stimuli, and stressful conditions for individuals such as 
psychiatric disorders and socially traumatic experiences [3]. The 
generation of a new proteostasis network implies an immediate role 
in protein synthesis, folding, disaggregation, or degradation, processes 
that encompass the translational machinery, molecular chaperones and 
their associated cochaperones, the ubiquitin-proteasome machinery, 
and the autophagy system.
The stress response to heat-shock was originally described in the 
early ‘60s by the Italian researcher Ferruccio Ritossa [4]. One of his 
colleagues accidentally switched the temperature of his incubator 
where Drosophila cells were grown, and a quite different puffing 
pattern was acquired by those cells. The biological consequence was an 
exceptional increase of transcriptional activity for a family of proteins 
that, for this particular reason, were generically named heat-shock 
proteins (HSPs). Then, it was noted that HSPs are expressed in a highly 
conserved manner in all organisms from bacteria to humans, to the 
point that many times they may be efficiently interchanged. HSPs 
form oligomeric complexes constitutively expressed under normal 
conditions (ranging up 5-10% of the total protein). They function as 
molecular chaperone machineries capable to regulate the folding of 
all proteins, intracellular transport of soluble and particulate cargoes 
among the different subcellular compartments, repair or degradation 
of proteins, refolding of misfolded proteins, etc. [5]. In addition to 
being constitutively expressed, HSPs are also greatly induced by the 
onset of stress (up to 15%). It should be noted that the terms HSP and 
chaperone are frequently used as synonyms. However, while all HSPs 
are always chaperones, not all chaperones are induced by heat-shock.
The biological function of molecular chaperones is not limited to 
solve abnormal situations, but they also have an active participation 
in the biological function of native factors such as steroid receptors, 
protein-kinases, transcription factors, enzymes, oncogenes, structural 
proteins, etc. Actually, the 90-kDa heat-shock protein, Hsp90, has 
more than four hundred client proteins [6].
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As it was stated above, those molecular chaperones induced by 
heat stress are also called HSPs. However, temperature is not the 
sole stimulus to trigger the stress response, but also a wide variety 
of other stimuli (UV radiation, chemicals, toxic compounds, metals, 
inappropriate pH or osmotic pressure, nutrient starvation, oxidants, 
fever, cancer, infections, neurodegenerative diseases, etc [7]). Also, 
the heat-shock response can come in handy during the normal growth 
cycle of the cells even without the existence of stressors in the medium.
The essential role of the heat-shock factor
The HSP genes are regulated by a master transcription factor, 
the HSF (Heat-Shock Factor) [2]. In vertebrates four HSF members 
have evolved (HSF1, HSF2, HSF3, and HSF4), the HSF1 being so far 
the most abundant and best characterized member of the family. The 
inactive monomer of HSF1 is cytoplasmic and forms oligomers with 
the Hsp90-based heterocomplex [8]. Upon the exposure of cells to 
stress, HSF1 homotrimerizes, translocates to the nucleus, and acquires 
specific DNA-binding and transcription-enhancing activities [9,10]. 
How stressing situations are sensed by the cell and conveyed to HSF1 
is not entirely understood. As mentioned before, a great number 
of stresses can trigger a heat-shock response, therefore it has been 
postulated that different types of molecular sensors may exist for each 
type of stimulus. Alternatively, it could be that a given proteotoxic 
environment may converge in a common signal able to initiate the 
biological response. The classical model postulates that under normal 
conditions, the association of molecular chaperones to HSF1 maintains 
this transcription factor inactive. When cells are subjected to stressing 
situations, the increased level of protein misfolding would release the 
Hsp90-based complex from HSF1 monomers allowing its trimerization 
[8,11]. Other models propose that HSF1 has itself the ability to detect 
proteotoxic conditions, as evidenced by the capacity of purified HSF1 
to homotrimerize in vitro upon the onset of different types of stresses [12]. 
The induction of the stress response results in high levels of 
expression of molecular chaperones, which bind to nascent chains 
and other metastable soluble proteins preventing misfolding and/
or aggregation. During the attenuation of stress and the subsequent 
recovery steps, the pool of non-native proteins dissipates and 
protein homeostasis is therefore restored. However the persistence 
of the original problem may perpetuate mechanisms responsible for 
proteostasis maintenance by constant activation of influencers. This is 
manifested with the existence of a steady-state in pathologies such as 
Alzheimer’s disease, chronic emotional distress, psychiatric diseases, 
cancer, and diabetes [1]. 
Molecular chaperones
The molecular chaperone family comprises a very heterogeneous 
group of proteins that may be grouped into eight subfamilies [1,13,14]: 
1)-The small HSPs/α-crystalin group, which show molecular weight 
ranging from 12-kDa to 43-kDa. There are 10 mammalian sHSPs, all of 
them are cytosolic and most of which contain an α-crystalline domain 
[15]. They favour the client protein refolding by Hsp70 by forming large 
homo-oligomeric cages able to trap misfolded proteins and preventing 
the formation of undesirable intra-or intermolecular interactions. 
This process is ATP-independent and thought to be complementary 
for those commanded by other ATP-dependent chaperones. 2) The 
DNAJ/Hsp40 subfamily, characterized by the presence of a J domain 
that permits interactions with Hsp70. These chaperones can be 
thought of as adaptors that provide versatility to Hsp70 function [16] 
assisting protein refolding by presenting misfolded proteins to Hsp70 
and by enhancing its ATPase activity. 3)- The Hsp60 mitochondrial 
chaperonin-like protein is essential for maturation and maintenance 
of the mitochondrial proteome and is therefore intimately linked to 
energy production [13]. 4)- The Hsc70/Hsp70 subfamily of chaperones 
with intrinsic ATPasa activity that is enhanced by Hsp40. It works 
in a cooperative fashion with Hsp90 in several heterocomplexes, and 
is also recruited to newly synthesized polypeptides by the ribosome-
associated complex [17]. Importantly, Hsp70 shows antiapoptotic 
properties [18]. 5) The Hsp90 scaffold protein is able to form large 
heterocomplexes with other chaperones and cochaperones. It is 
perhaps the most versatile protein of the entire family and certainly 
is the most abundant soluble protein of the cell [19]. 6)- The large 
HSPs/Clp subfamily of AAA+ ATPases (molecular weight of 100-kDa 
to 110-kDa), which have the ability to solubilise almost any protein 
that becomes aggregated after severe stress, but are not required under 
normal growth conditions [20]. They work associated with Hsp70 
extracting trapped polypeptides from aggregates via a threading 
mechanism. 7)- An additional group comprises chaperones present 
in the endoplasmic reticulum that participates in the proper folding 
and eventual degradation of new born proteins, such as the glucose 
regulating proteins (Grp), the ubiquitine and lectin chaperones 
calnexin and calreticulin. 8)- Immunophilis, endogenous proteins 
that are characterized by the presence of a signature domain named 
PPIase (peptidyl-prolyl-(cis/trans)-isomerase), i.e., an enzymatic 
activity of isomerase able to interconvert reversibly Xaa-Pro bonds 
High molecular weight immunophilins are frequently bound to Hsp90 
playing the role of cochaperones or forming a functional regulatory 
unit with the chaperone [21,22].
The Hsp90-Hsp70-Immunophilin complex
Both chaperones Hsp90 and Hsp70 are highly expressed in all 
types of cells, and they cooperate in most of the complexes with client 
proteins. The cytoplasmic pool of Hsp90 forms homodimers, each 
monomer unit consisting of three domains: a) The N-terminal domain 
contains an ATP binding site whose hydrolysis to ADP is critical in the 
chaperoning activity of the Hsp90 homodimer. b) The M- domain is 
a flexible middle region able to interact with a great numbers of client 
proteins and is linked to the N-terminal domain by a highly charged 
linker sequence. The intrinsic ATPase activity of Hsp90 requires an 
arginine located in the “catalytic loop” of the middle domain [23]. c) The 
C-terminal domain is responsible for the dimerization of the chaperone 
and also possesses a key pentapeptide MEEVD sequence that permits 
the association of TPR-domain proteins such as immunophilins, Hop, 
WISp39, Tom70, CHIP, Tah1, etc. [19,24,25].
Dimers of Hsp90 are in dynamic equilibrium between two states, 
the ADP-bound isoform and the ATP-bound isoform, which are able 
to form different oligomeric heterocomplexes with other chaperones 
(Figure 1-A). The ADP-bound Hsp90 shows higher affinity for the TPR-
domain-containing cochaperone Hop. Hop brings together Hsp70 
and Hsp90. Hop also prevents Hsp90 from effectively chaperoning 
client proteins whose binding favours a high, sustained level of ATP 
[26,27]. Hop binding to Hsp90 blocks ATP binding and the ATPase 
activity of the chaperone, which makes binding of the cochaperone 
p23 significantly weak or void [28,29]. This ADP-bound conformation 
of Hsp90 is favoured by the Hsp90 disrupting agent geldanamycin, a 
benzoquinone ansamycin antibiotic that shows high affinity for the 
nucleotide binding site of the chaperone. In this state, the associations 
of both p23 and TPR-domain immunophilins to the complex are 
impaired. On the other hand, when ADP is exchanged with ATP, the 
ATP-bound isoform of Hsp90 is stabilized by p23 binding, and other 
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TPR proteins such as the high molecular weight immunophilins are 
efficiently recruited [26,27]. The ATP-bound isoform of Hsp90 is a 
better modulator of the biological activity of client proteins. It appears 
that p23 binding to Hsp90 changes the nature of ATP binding to 
Hsp90 and prevents the intrinsic ATPase activity of the chaperone 
[30], which in turn may affect the biological activity of the Hsp90-
bound client factor. Hsp90 interacts with hundreds of client proteins 
and other signaling molecules, including steroid receptors, p53, 
tyrosine-kinases, oncogenes, Stat5, NOS, HSF1, Akt, Chk1, Mdm2, IκB 
kinases, cytoskeletal proteins, importins, nucleoporins, histones, DNA 
helicases, telomerase reverse transcriptase, DNA polymerases, SmyD 
methyltransferases, p300 acetyltransferase, HDAC6, Aha1, SGT1, 
and Cdc37. In other words, Hsp90 creates a broad scaffold platform 
for the regulation of signalling cascades, nuclear architecture and cell 
function [28,31,32]. The mechanism involved in client protein-Hsp90 
interaction also involves the ATPase intrinsic activy of the chaperone. 
Thus, Hsp90 exists in a conformational equilibrium between two states 
an open (V-shaped) conformation and a close conformation (Figure 
1-B), a state where ATP-hydrolysis takes place, the N-terminal domains 
dissociate, and Hsp90 returns to the open conformation again [33].
Perhaps one of the most remarkable biological functions of 
high molecular weight immunophilins associated to Hsp90/Hsp70 
complexes is the ability to interact with the dynein/dynactin motor 
complex [34], a property used to favour the retrotransport of soluble 
factors in an active manner using cytoskeletal tracks. This machinery is 
used for the transport of proteins such as GR [35], MR [36], ecdysone 
receptor [37], RAC3/AIF complexes [38], NF-κB [39], etc., as well as 
for viral particles when cells are infected by a virus [40]. Importantly, 
Hsp90-based complexes have been related to microbial invasion of 
host cells [41,42] and increased antigenicity of pathogen soluble factors 
[43].
Role of heat-shock proteins in immunity
The best biological incentive to trigger the innate immunity 
response is the exposure to a foreign molecule in a hazardous milieu. 
The critical decision of an organism for responding or ignoring that 
stimulus is taken by innate immune recognition receptors upon 
their activation by PAMP ( pathogen-associated molecular patterns) 
molecules, i.e. factors associated with groups of pathogens that are 
small molecular motifs conserved within a class of pathogens (for 
example lipopolysaccharides, bacterial CpG DNA, etc.) and recognized 
by cells of the innate immune system by PRRs (or Pattern Recognition 
Receptors) [44]. A number of these PRRs have been cloned and 
showed to belong to the expanding family of toll-like receptors (TLRs). 
An alternative pathway for the activation of innate immunity is that 
proposed by the ‘danger theory’ [45]. According to this hypothesis, 
the innate immunity can be additionally activated by endogenous 
substances released by the damaged or stressed tissue itself. In this way, 
stressed cells can messenger stress to other cells of any type. Some of 
the stress signals released by cells are the HSPs induced in response to 
the insult, such that they are potential candidates for signalling tissue 
damage or cellular stress. In this regard, some of them such as Hsp60 
and Hsp70 have been actually found capable of signalling through 
CD14, TLR-2, and TLR-4 [46,47].
The first findings reported a heat-shock-like protein described as 
a glia-axon transfer protein of the squid giant axon [48], as well as the 
Figure 2. Schematic mechanism for the role of exported heat-shock proteins in the 
pathogenesis of autoimmunity. 
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Figure 1. (A) ATP-dependent conformational states of Hsp90. Dimers of Hsp90 adopt 
different conformation when ATP or ADP is bound. The best chaperone activity for a given 
client protein is reached by the ATP form of the dimer, which is also able to interact more 
efficiently with TPR-domain immunophilins (IMM) and the cochaperone p23. This optimal 
conformation is stabilized by molybdate, perhaps due to its conformational similarity 
with the hydrolyzed gamma phosphate of ATP (released by the intrinsic ATPase activity 
of Hsp90). On the other hand, the ADP-dependent conformation favors the association 
of the TPR-domain cochaperone Hop rather than IMM binding. The ADP-dependent 
form of Hsp90 is stabilized by the benzoquinone ansamycin geldanamycin (GA) when 
the drug replaces the ADP from its pocket. The lower efficiency of this dimer to interact 
with client proteins compared to its ATP isoform, usually targets the destabilized client 
factor to degradation by the proteasome. (B) Conformational Cycle of Hsp90 Dimers 
Interacting with a Client Protein.  The V-shaped open conformation of Hsp90 binds ATP at 
the N-terminal domain (N). The M-middle domain (M) repositions and interacts with the 
N-domain, and the dimer twists over itself. The intrinsic ATPase activity is favored by this 
close association of the M and N domains leading to the separation of the N-domains to 
release the products of the hydrolysis, and Hsp90 returns to the original open conformation 
to restart the cycle. The C-terminal domain (C) maintains Hsp90 as a dimer.
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fact that Hsp70 is released from cells by a mechanism not impaired 
by inhibitors of the known secretory pathways [49]. This original early 
observation was deemed not relevant, and the presence of HSPs in the 
extracellular environment was disregarded for many years until it was 
demonstrated that recombinant Hsp70 activates cells of the immune 
system [50]. These findings were disputed based on the possibility 
that the activation of immune cells was due to contamination [51,52]. 
Nonetheless, these worries were ruled out after experiments using 
pure recombinant Hsp70 isolated from insect cells, non-recombinant 
Hsp70, treatments with antibiotics, boiling treatments, incubation in 
serum free media, etc. [53,54]. Today, it is well established and broadly 
accepted that Hsp70 is responsible for the activation of macrophages, 
monocytes, dendritic cells, natural killer cells, hepatocytes, etc. [55-
58]. Moreover, extracellular HSPs have been shown to work as potent 
immunostimulatory or immunosuppressive molecules depending on 
the circumstances by which they interact with cells [59].
In addition to Hsp70, other HSPs have also been found in the 
extracellular milieu, such as Hsp60 [60], Hsp90 [61-63], Grp78/
BIP [64,65], and Hsp27 [66]. The biological relevance of these 
extracellular factors has been reinforced by the detection of Hsp70 in 
the serum of patients suffering from a number of pathologies such as 
chronic inflammation [67], myocardial infarction [68], lung injury 
[69], coronary artery disease [70,71], infections [67], cancer [72,73], 
ischemia/reperfusion events [74], diabetes [75], hypertension during 
pregnancy [76], etc. HSPs can also be detected in the serum of healthy 
individuals, although at lower levels [59]. Importantly, the presence of 
Hsp70 in plasma is correlated with improved survival of critically ill 
patients [77,78]. Other extracellular HSPs such as Hsp27 [66], Hsp60 
[79], and Hsp90 [61,80] have also been linked to several diseases such 
as pancreatic carcinoma, coronary heart disease, cancer metastasis or 
systemic lupus erythematosus. 
Heat-shock protein secretion
Regarding the origin of extracellular HSPs, while it was originally 
demonstrated a basal HSP release from healthy cells [49], others 
researchers proposed that the source of extracellular HSPs could be the 
consequence of cell lysis after necrosis [81]. Later on it was demonstrated 
that HSPs are released by an active mechanism independent of cell 
death [82]. Nevertheless, these studies cannot preclude the possibility 
that necrosis could be an additional source of extracellular HSPs, so two 
different sources of extracellular HSPs can coexist the active pathway 
due to a non-conventional secretory mechanism, and a passive one 
secondary to cell death and subsequent lysis [55,83]. 
Following HSP release from external pathogens, foreign cells, 
autologous inflamed or necrotizing tissue (such as tumours or those 
target tissues of autoimmune diseases), they are recognized by 
receptors expressed in the surface of immune cells of the host TLR-
4, TLR-4 like, TLR-2, CD14, CD91, CD94, LOX-1, SR-A, or as an 
immunodominant antigens [55,84,85] 8–11. With the contribution 
of these released HSPs, the immune system of the host is therefore 
“informed” about the presence of pathologic processes (Figure 2).
The secretion mechanism of Hsp70 is perhaps the most studied, 
although definitive conclusions are still uncertain. An active mechanism 
for Hsp70 secretion has not be demonstrated to date, whereas typical 
inhibitors of the classic endoplasmic reticulum-Golgi pathway, such 
as brefaldin-A, showed no effect on the release of Hsp70 [49]. On the 
other hand, this chaperone does not possess a consensus peptide signal 
for secretion via the classic ER-Golgi pathway. Therefore, it is likely that 
the export mechanism is via a putative alternative pathway called the 
non-classical or unconventional secretory pathway [86], which could 
also be shared by other factors such as some interleukins, galectins, 
and growth factors, although unifying common steps for this proposed 
mechanism remain still unrevealed [86]. Three possible scenarios 
for Hsp70 active secretion could be its export a)- via the lysosome-
endosome pathway, in which Hsp70 is translocated into the lysosome 
lumen via ATP-binding cassette (ABC) transport-like system and 
further transported outside cells via the endocytic process [87]; b)- via 
secretory-like granules loaded of Hsp70 in similar manner as to those 
granules used by exocrine cells and the endocrine and neuroendocrine 
systems to release hormones and granines in secretory vesicles [88]; and 
c)- via extracellular vesicles [55] derived from the plasma membrane 
by membrane blebbing, ectosome vesicles, and/or by endocytosis, i.e., 
due to the formation of multiple vesicles with the same topology as 
the plasma membrane (exosomes) [89]. Regardless of the origin of the 
vesicles, other HSPs such as Hsp90, Hsp60, Hsp27, Grp78/BIP have 
also been detected in the lumen and membrane of these extracellular 
vesicles [90]. It is thought that the HSPs in the lumen of the vesicle 
are the consequence of protein being trapped during the formation of 
the vesicle since HSPs are very abundant in the cytosol. Therefore, it is 
expected that vesicles should burst to release the intravesicular HSPs 
allowing them to interact with other proteins and cells. Alternatively, 
vesicles can fuse with the membranes of cells, releasing the lumen 
content into the cytosol as well as those HSP associated with the vesicle 
membrane, as reported for Hsp70 [53,91] and Hsp60 [60,92]. HSPs 
are highly concentrated in the vesicles (for example, in the mM order 
for Hsp70 [55]), which favours interactions with other factors and cell 
surface receptors increasing the biological activity of the chaperone. It 
has been reported that the specific activity of Hsp70 in these vesicles is 
more than 250 fold greater for activating macrophages than the soluble 
Hsp70 [55]. Similar to Hsp70, Hsp90 also lacks a secretory signal; 
therefore it has been postulated as being exported via exosomes [93,94] 
or by direct translocation across the plasma membrane [95].
Other molecular chaperones are also present in the external cell 
surface, such as Grp78/BIP [96], Grp94 on the plasma membrane of 
sarcoma cells [97], Hsp60 on the surface of human endothelial cells 
[98] and T cell-lines [99], as well as in mouse liver and spleen [100]. 
Hsp90, which was first detected on the cell surface of tumour cells 
[101], was subsequently found on monocytes [43], mesenchymal cells 
[102], and neuroblastoma cells [61,103]. 
Role of extracellular chaperones in immunity
Exported HSPs trapped the attention of several laboratories because 
of their potential action on the immune system, where which they 
function as signalling molecules. Accordingly, it has been stated that 
extracellular Hsp70 is able to activate monocytes, macrophages natural 
killer and dendritic cells [55]. Also, Hsp70 is a stimulating factor for 
autoimmunity [104,105] by a peptide-specific immune response that 
involves the α2-macroglobulin receptors CD91, CD40 and OLR1/LOX-
1 expressed in antigen-presenting cells [106]. The innate immunity 
response is triggered by recognition of toll-like receptor (TLR) signals, 
one of the activating signals being the exported HSPs. Thus, to evaluate 
if exported Hsp70 shows antigenic properties, isolated lymphocytes 
from rat spleens were exposed to purified Hsp70, and the result was 
lymphocyte proliferation [107]. Then, it was demonstrated that the 
immunogenic form of Hsp70 corresponds to a well-conserved 14 
amino acid sequence (amino acids 139–153) [108]. 
Additionally, HSPs can also play a role in generating antigen-
specific T cell responses [109] It is thought that complexed peptides 
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with Hsp70, Hsp90B1/gp96, calreticulin, etc. are delivered to antigen-
presenting cells by receptor-mediated internalization of the HSPs. This 
could make them available for further processing and presentation to 
the major histocompatibility complex. Inasmuch as specific receptor-
mediated mechanisms exist for binding and internalization of HSPs 
[110], it may be envisaged that the cross-presentation of HSP-derived 
antigenic determinants is a realistic mechanism for cross-priming by 
antigen-presenting cells. Consequently, it is logical to propose that 
these HSPs highly induced in several types of pathologies are indeed 
targets of the adaptive immune response. 
It has been demonstarted that exported Hsp70 increases neutrophil 
chemotaxis and their microbicidal ability [111], as well as macrophage 
phagocytosis properties [112], and modulation of the response of 
monocytes to endotoxin [113]. Similarly, extracellular Hsp70 is related 
to both immunostimulatory and immunosuppressive activities [114]. 
Nonetheless, the exact molecular mechanisms responsible for such 
modulation of the response of cells of the immune system are still 
poorly understood. It was reported that during the inflammatory 
response generated by tumours, both IFN-γ and IL-10 induce the active 
release of both Hsp70 isoforms Hsc73 and Hsp72) from the malignant 
tissue [115]. It is still uncertain whether these secreted HSPs produce 
antitumour immunogenicity responses. 
Taking advantage of the capability of HSPs to target a chaperoned 
antigen to antigen-presenting cells and elicit cross-presentation, it has 
been developed immunotherapy strategies using the secretable forms of 
HSPs. Thus, it is known that the Hsp90B1/gp96 secreted from tumour 
cells carries an antigenic peptide able to activate specific antitumour 
cytotoxic T lymphocyte responses [116]. This property is also shared 
by exported Hsp70 and Hsp90 [117]. The endoplasmic reticulum 
chaperone BiP (Binding of immunoglobulin protein) is also exported 
from tumour tissues and capable to elicit antigen-specific tumour 
immunity [118]. This secreted BiP complexed with antigenic peptides 
is taken up by dendritic cells and cross- presented in association 
with MHC class I molecules. This leads to cytotoxic T lymphocyte 
responses, which in turn stimulates tumour cells to produce their own 
endogenous “cellular vaccine”. Such immunogenic strategy could be 
more advantageous than a peptide-generated vaccine approach because 
single peptide-based cancer vaccines have certain disadvantages. For 
example, single peptide vaccination usually induces a HLA-restricted 
cytotoxic T lymphocyte response, thereby allowing tumour cells to 
escape from lymphocyte recognition. Contrarily, because HSPs are 
associated to a broad-spectrum antigenic peptide repertoire, it is likely 
that the subsequent induction of a cytotoxic T lymphocyte response 
is more effective because it is directed against multiple antigens. In 
addition, this type of secreted HSP-based cancer vaccine may be useful 
for all classes of patients regardless of HLA restrictions. In short, gene 
modification of HSPs for secretion could be a practical strategy to 
provide an exceptional beneficial approach for cancer immunotherapy.
Similar to cytoplasmic chaperones, it has been proposed that 
Hsp90B1/gp6, an endoplasmic reticulum-resident partner of the 
chaperone Hsp90, might participate in mechanisms that are critical for 
cell growth, differentiation, and responses to endoplasmic reticulum 
stress [119]. Also, it is a natural adjuvant for chaperoning antigenic 
self peptides into the immune surveillance pathways, and may also 
be involved in the maintenance of morphostasis and self tolerance. 
Recently, it was demonstrated that high levels of up-regulation of 
Hsp90B1/gp96 in regenerating liver and thymus are followed by signs 
of transient autoimmunity, augmented apoptosis in thymus, and 
the presence of autoreactive NKT and regulatory T cells that might 
be involved in the control of rapid liver growth induced by partial 
hepatectomy [120].
Hsp90 is a key regulator of innate immunity
It is accepted that exogenous antigens are processed by two main 
pathways [83,121]: a)- the classical MHC class I loading pathway 
involving the transporter-associated antigen-presenting (TAP)-
dependent pathway, and b)- the endosome-recycling pathway, which 
involves a post-Golgi loading mechanism of MHC class I in endocytic 
compartments. It has been demonstrated that soluble Hsp90 is able to 
translocate extracellular antigens from endosome to cytosol for TAP-
dependent cross-presentation [122], where antigens are processed in 
the endosomes by cathepsin S and other peptidases, and thereafter 
are loaded in endocytic compartments onto MHC class I molecules. 
These complexes are recycled from plasma membranes [123,124]. 
Hsp90 also works as an efficient route-finder for those chaperoned 
antigens targeted to the cross-presentation pathway [125,126]. Also, 
it has recently been demonstrated that Hsp90-cancer antigen peptide 
complexes are efficiently cross-presented by monocyte-derived 
dendritic cells and stimulated peptide-specific cytotoxic T lymphocyte 
responses [127]. Also, it was demonstrated [128] that stimulation of 
CD4+T cells by dendritic cells DC that had been activated by Hsp90-
peptide complexes involved pathways that share many of the essentials 
mechanisms involved in stimulation of antigen cross presentation.
Hsp90 empowers the chaperoned ligands to activate an immune 
response. It is well known that unmethylated single-stranded DNA 
containing a cytosine–phosphate–guanine (CpG) motif binds TLR9 
receptors of plasmacytoid dendritic cells (pDCs) and B cells, which 
results in the production of IFN-α [129]. However, these cells normally 
do not respond to self-DNA, a phenomenon that was explained by the 
fact that both bacterial and viral DNA have multiple CpG nucleotides 
able to bind and consequently activate TLR9 more efficiently than 
mammalian self-DNA contains, which contains a lower number 
of these motifs and are usually masked by methylation. There are 
situations where self-DNA might have the potential to activate TLR9, 
but it may not succeed since it fails to access the TLR9-containing 
endolysosomal compartments [130]. Synthetic CpG-DNAs have been 
assayed CpG-A, able to stimulate the receptors of pDC cells and 
produce IFN-α, and CpG-B, which is inactive in this regard [130], but 
stimulates the release of IL-6 and TNF-α in these cells. While CpG-A 
forms large multimeric aggregates and is retained for long periods 
of time in early endosomes, whereas CpG-B is a monomer, cannot 
oligomerize, and rapidly translocate from early to late endosomes 
or lysosomes of pDCs [131]. Such a long-lasting retention of CpG-A 
results in prolonged activation of TLR9 signaling, leading to strong 
IFN-α production. In other words, the retention time of the CpG/ 
TLR9 complex in endosomes is a key determinant for the TLR9-
dependent signalling cascade. Inasmuch as Hsp90 binds and retains 
client ligands within early endosomes, studies specifically conducted to 
evaluate the role of such interaction demonstrated that human pDCs 
pulse Hsp90•CpG-A complexes inducing a larger production of IFN-α 
than the monomeric CpG-A [130]. In contrast to human dendritic 
cells, murine cells also express TLR7 receptor in addition to TLR9 
[132]. In this system, the Hsp90•CpG-A complex is retained within 
early endosomes for longer periods leading to sustained activation 
of murine cells and eliciting TLR9 signaling for IFN-α production, 
which is indeed TLR9-mediated since TLR9 KO cells do not produce 
IFN-α. By contrast, CpG-A alone was transfered to late endosomes 
and lysosomes. Importantly, not only CpG-A•Hsp90 complexes, but 
also CpG-B•Hsp90 complexes are strong stimulating ligands of TLR9 
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resulting in high production of IFN-α. 
It may be stated that extracellular Hsp90 has the capacity to 
chaperone CpGs in early endosomes leading to a more abundant 
production IFN-α. Therefore, there are two important considerations 
derived from that property: a)- extracellular Hsp90 (and HSPs in 
general) could play a crucial role in the pathogenesis of nucleic 
acid-mediated autoimmune diseases, for example in systemic lupus 
erythematosus; and b)- it may be implied that the use of extracellular 
HSPs in combination with CpG may enhance the biological 
effectiveness of cancer vaccines. 
Heat-shock proteins and autoimmune diseases
The participation of HSPs in the pathogenesis of autoimmune 
diseases has been analyzed using two basic animal models: a)- artificially 
induced arthritis by the natural saturated terpenoid alkane pristane, 
adjuvant-induced arthritis, avridine-induced arthritis, arthritis 
generated by Streptococcus cell wall and collagen type II [133]; and 
b)- insulin-dependent diabetes mellitus model in non-obese diabetic 
mice (NOD)[134]. The adjuvant-induced arthritis is generated by 
intracutaneous injection with heat-killed Mycobacterium tuberculosis. 
Arthritis can be transferred from diseased injected animals to healthy 
naive animals with a single T cell clone specific for a particular sequence 
of Hsp60 M. tuberculosis isoform. Thus, the microbial agent initiates 
a self-perpetuating autoimmune process in a susceptible individual 
generating antibodies against the host’s Hsp60, and perhaps an epitope 
of the cartilage proteoglycan [135]. Regarding the potential advantages 
of this phenomenon from the perspective of therapeutic applications, 
it was observed the induction of tolerance after immunization with the 
HSP. Accordingly, pristine oil-generated arthritis disease shows high 
levels of IL-2 and IFN-γ after in vitro restimulation of arthritic mice 
splenocytes with mycobacterial Hsp60 [136].Therefore, mycobacterial 
Hsp60 is capable of preimmunize mice and protected them from 
pristane actions. 
Similarly, anti-Hsp70 antibodies have been found in the sera of 
patients with malaria [137]. HSPs have been shown to play a cardinal 
role in antigen direct presentation and cross-presentation leading to 
CD8+ T cell activation [109]. There is strong evidence to support the 
notion that cytosolic HSPs such as Hsp70 and Hsp90, and those of the 
endopasmic reticulum such as Hsp90B1/gp96, have the ability to bind 
antigenic peptides generated within the cells, as well as they are also 
part of the endogenous pathway of antigen presentation via the major 
histocompatibility complex class I molecules [138,139]. Peptides that 
are chaperoned by HSPs when released extracellularly, or HSP-peptide 
complexes assambled in vitro, are taken up by antigen-presenting cells 
such as dendritic cells via α2-macroglobulin receptor (CD91)-mediated 
endocytosis, resulting in representation by the major histocompatibility 
complex molecules [138,140]. Vaccination of mice with Hsp70, Hsp90 
and Hsp90B1/gp96 isolated from murine tumour cells elicits immune 
response sufficient for tumour rejection and suppression of metastatic 
tumour progression [141]. This tumour immunity was shown to result 
from tumour-derived peptides associated with the HSPs, rather than 
from the HSPs themselves [117].
Insulin-dependent diabetes mellitus is the other example of Hsp60 
involvement in autoimmune diseases. The regular disease is the clinical 
consequence of pancreas β-cell destruction by T cells. Infection of non-
obese diabetic mice with M. avium prevents the development of diabetes 
[142]. Similarly immunization of NOD mice with mycobacterial Hsp60 
significantly reduces the incidence of the disease [143], suggesting that 
autoantibodies against Hsp60 could play a major role in the etiology of 
this type of diabetes.
Systemic lupus erythematosus is other prototype of autoimmune 
disease characterized by the presence of plasma autoantibodies against 
self-nuclear structures, such as dsDNA and RNA-containing antigens, 
including Sm and RNP [144,145]. This disease is characterized by 
the presence of autoantibodies against Hsp90 [146] and enhanced 
expression of Hsp90 in peripheral blood mononuclear cells of patients 
[147]. Cytosolic Hsp90 translocates to the nuclear compartment under 
stressful conditions, which raises the possibility that Hsp90 may bind 
self-DNA in the nucleus. In a following step, self-DNA associated 
with endogenous Hsp90 can be released into the extracellular milieu 
when cells undergo necrosis, triggering the production of IFN-α 
by denditric cells. Serum Hsp90α levels has been found increased 
in patients with lupus [148,149], and these high concentrations are 
significantly decreased after treatment. Moreover, immunodepletion of 
extracellular Hsp90 from serum decreased IFN-α production by pDCs 
[148], indicating that depletion of Hsp90 might induce remission 
and prevent end-organ damage. Thus, control of deregulated pDC 
activation and IFN-α production represents an attractive treatment 
strategy for systemic lupus erythematosus. 
Collectively, extracellular Hsp90 plays a crucial role in the 
disease activity of SLE and that Hsp90 inhibitors have promise for 
the treatment of IFN-α-mediated autoimmune diseases. In line with 
this postulate, it has recently been reported the evaluation of small 
molecule inhibitors of Hsp90 as potential therapeutic target for this 
disease in an autoimmune mouse model [150]. The novel resorcinolic 
triazolone inhibitor STA9090/ganetespib [151] was found to be 
equally efficacious and tolerable when compared to an effective weekly 
dosing regimen of the standard-of-care immunosuppressive agent 
cyclophosphamide. Importantly, co-treatment of ganetespib with a sub 
optimal, intermittent dosing schedule of cyclophosphamide resulted 
in superior therapeutic indices and maximal disease control. These 
findings highlight the potential of HSP90 inhibition as an alternative, 
and potentially complementary, strategy for therapeutic intervention 
in systemic lupus erythematosus.
HSPs in the Autoimmune Diseases of the central ner-
vous system (CNS)
The very first reports of HSPs release from neuronal cells were 
related with the secretion of both Hsp70 and Hsp110 along with actin 
[49]. Further publications reported that Hsp70 is released from glial cells 
and taken up by adjacent neurons [48,152]. It has been demonstrated 
that many neurons have reduced expression of some HSPs due to 
inadequate HSP gene transcription activity [153]. However glial cells 
adjacent to synapses release HSPs into the extracellular medium and 
chaperones are captured by neuronal receptors [152,154,155]. The 
functions of such non-neuronal HSPs are not properly understood 
to date, but probably they may provide some chaperoning properties 
to neurons and protection from programmed cell death, which can 
accompany neurotransmission [155].
In view of the limited regenerative capacity of CNS, protection 
against immune responses requires special mechanisms of self defence. 
This is achieved due to singular conditions able to reduce the exposure 
to the immune system, referred to as ‘immune privilege’ [156]. This 
is possible due to the existence of blood-brain barrier, the limited 
expression of major histocompatibility complex molecules of the 
brain, and neuronal expression of molecules with immunosuppressive 
properties, e.g. TGF-β and CD200. These characteristics contribute to 
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protect neurons from microglia and T-cell-induced damage. However 
activated immune cells can invade the CNS under specific conditions 
through selective receptor-ligand interactions [157],  and the list of 
neurological diseases where T cells are involved in targeting neurons 
or their axons, directly or indirectly, is continuously growing [158]. 
The most frequent diseases where the immune system targets neurons 
are multiple sclerosis, the paraneoplastic cerebellar degeneration, and 
Parkinson’s disease. 
Multiple sclerosis is a multifocal inflammatory autoimmune 
disease affecting only the CNS in which the target is the myelin and 
the myelin-producing cells, oligodendrocytes. This disease may 
be considered a standard model of an autoimmune disease of the 
CNS from the perspective of the molecular mechanism of action of 
HSPs. Myelin is destroyed in patches, resulting in the formation of 
astrocytic scars (or plaques), showing high accumulation of T cells and 
macrophages, increased concentrations of cytokines and chemokines, 
and antibodies to myelin proteins [159]. Although the exact etiology of 
the disease is not fully understood, current evidence suggests a critical 
role for the immune system in its pathogenesis. The inflammatory and 
oxidative environment generated in the CNS of these patients favours 
the overexpression of most of HSPs, including Hsp70 [160,161], 
whose induction occurs predominantly in oligodendrocytes [162]. 
The biological consequences of Hsp70 induction are dual. Based on 
their activity as chaperone, the release of Hsp70 into the milieu act 
as an adjuvant that binds immunogenic peptides, which increases the 
inflammatory local reaction and autoimmunity. On the other hand, 
Hsp70 is an antiapoptotic factor [18,163,164] and, as all chaperones 
do, it prevents the accumulation of abnormal protein aggregates [165], 
a common histopathological hallmark that contributes to neuronal 
degeneration [166]. Therefore, inadequate induction of Hsp70 can 
increase the rate of protein aggregation upon the onset of stressing 
situations leading to apoptosis, a typical end for most neurodegenerative 
and autoimmune diseases such as multiple sclerosis. Accordingly, it has 
been reported that Hsp70 overexpression in neuronal cell cultures and 
also mouse models of neurodegenerative diseases shows advantageous 
actions to ameliorate the severity of the phenotypes by reducing the 
number and size of inclusion bodies and the accumulation of disease-
causing factors [161].
Since Hsp70 works as a neuroprotective factor for ischemia-
induced cell death [167], it may be argued that the overexpression 
of the chaperone in multiple sclerosis lesions might protect the CNS 
against the typical inflammatory environment of this disease [168]. In 
line with this, it has been demonstrated that the stimulating action of 
proinflammatory cytokines (IL-1, TNFα, IFN-, etc.) in glial cells induce 
Hsp70 expression, which in turn exerts favourable final effects on glial 
cells and neurons [162]. However, all coins have two sides. At the same 
time, exported Hsp70 leads to the activation of the NF-κB transcription 
factor due to the activation of TLRs; this induces the production of 
proinflammatory cytokines (IL-12, IL-1β, IL-6, TNF-α, and GM-CSF) 
[50,81,135], chemokine secretion (MCP-1, RANTES, and MIP-1α) 
[169], and nitric oxide production [170] by macrophages and dendritic 
cells. Moreover, extracellular Hsp70 enhances the expression of CD83, 
CD86, CD40 and the major histocompatibility complex class II on 
dendritic cells, as well as the migration of these cells to draining lymph 
nodes [81,171]. All of these elicit priming adaptive immune responses. 
Therefore, it is thought that the acute stress induces the release of 
Hsp70, which works as a danger signal to prepare the immune system 
against a possible pathogen challenge.
Taken all together the above exposed observations together, it can 
be concluded that the inflammatory phase occurring at the initial stages 
of multiple sclerosis is a sort of preconditioning stimulus for glial cells 
to induce Hsp70 expression and release, which in turn has a protective 
action on neurons in the subsequent neurodegenerative phase. This 
permits to envisage an obvious scenario a failure to induce Hsp70 
or the insufficient production of HSPs in the CNS is a possible 
determining factor for multiple sclerosis development, and conducts 
to postulate therapeutic strategies focusing on HSP up-regulation for 
different neuropathologies. This logical hypothesis, however, cannot be 
applied for the case of multiple sclerosis because there is an additional 
conflicting factor the strong autoimmune reaction that accompanies 
multiple sclerosis triggers a process of neurodegenerative damage that 
leads to the typical clinical signs of the disease. Thus, extracellular 
Hsp70 is actually a harmful rather than beneficial factor. Compared to 
other CNS pathologies such as Alzheimer’s and Parkinson’s diseases, 
the released Hsp70 in multiple sclerosis strongly exacerbates the 
immune response by acting as a very efficient adjuvant for myelin 
peptides and as a proinflammatory cytokine [172]. These effects cannot 
be counterbalanced by Hsp70 beneficial actions such as the reduction 
of protein misfolding or antiapoptotic effects. These concepts are 
particularly valid for viral infections. Researchers are considering the 
possibility that viruses, and also bacterial infections, may cause multiple 
sclerosis. Viruses are known to cause inflammation and a breakdown of 
myelin (or demyelination). Therefore, it is highly possible that a virus 
could trigger the disease. Several viruses and bacteria are currently 
being investigated to determine if they are involved in the development 
of multiple sclerosis. These studies include measles virus, human 
herpes virus-6 (HHV-6), and Epstein-Barr virus (EBV).
All these features can also been observed in autoimmune diseases 
such as glaucomatous pathology, where elevated serum titers of 
autoantibodies to many optic nerve components [173] and retina 
antigens [174] are present, as well as abnormal T-cell subsets [175]. In 
this case the master chaperoned involved in the disease is Hsp27. In 
addition to the intrinsic neuroprotective functions of Hsp27, like other 
HSPs, this chaperone also serves as an antigenic stimulus activating 
the innate and adaptive immune response during glaucomatous 
neurodegeneration [176]. By serving as a danger signal, up-regulation 
of Hsp27 may facilitate detection and elimination of stressed retinal 
ganglion cells by the immune system. Thus, uncontrolled immune 
activity, including T-cell mediated cytotoxicity to retinal ganglion 
cells and their axons, may eventually facilitate the progression of 
neurodegeneration. In summary, the overall summary of these 
biological events tells us that potential errors during the processing 
of the native cellular interactions are relevant for the conversion of 
protective immunity and self-limiting inflammatory responses into 
chronic neurodegeneration and autoimmune diseases. 
Concluding remarks
The export of HSPs is still a poorly understood process as a 
consequence of our reduced understanding of the actual mechanism 
for the release of the chaperones and the lack of a standard action in 
that extracellular milieu, with biological consequences that are even 
opposite to the classical and broadly accepted actions of the these 
proteins. One piece of evidence, however, is clear today after so many 
years of controversy: the extracellular HSPs are not artefacts. They 
play roles as extracellular factors ranging from ligands to activate 
cell surface receptors to favour antigenicity of pathogenic factors, 
such that autoimmune responses are developed. The overall function 
of these chaperones seems to be at the level of signalling or cellular 
communication rather than at the traditional chaperone activity. In 
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this regard, to date no overwhelming experimental evidence exist that 
allow us to affirm that extracellular HSPs play the same chaperone 
activity outside cells, to the point that the requirement of co-chaperones 
and other factors associated to them for playing their intracellular 
roles are unlikely  not required for their extracellular functions as 
signalling molecules. A particularly relevant effect is the modulation 
of the immune system, which is visualized as a novel priming event for 
cellular communication under stressing situations. Ultimately, these 
exported molecular chaperones represent a new opportunity to explore 
eventual therapeutic approaches to modulate the biological response 
of exported HSPs in the development and progression of autoimmune 
diseases.
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